GlaxoSmithKline (GSK) is currently experiencing significant movements in its stocks due to a variety of factors. There has been a significant expansion of GSK's
share buyback program, increasing its
Treasury stock to over 6% of voting rights in two instances. GSK has out-licensed rights for a
rare liver disease drug to Alfasigma. Strong performance across its specialty medicines has pushed the full-year outlook upwards. The company's shares have fallen due to the narrow approval of a
blood cancer drug, potentially limiting its US relaunch. GSK is eyeing a whopping $55 billion in sales that are unrelated to obesity. It added a significant number of shares to its Treasury in its ongoing buyback program. The company's stock has jumped nearly 19% in 3 months, prompting speculation about whether to buy, hold, or sell. CEO exits have led to a surge in stock prices, while GSK's
$30 billion US gamble has sent pharmaceutical stocks skyrocketing after the Trump pricing deal. Significant developments on the company's predictions for 2025 have sparked discussion about its value, with cancer and HIV drug sales providing a boost for GSK’s shares.
GSK Stocks News Analytics from Wed, 18 Jun 2025 07:00:00 GMT to Fri, 13 Mar 2026 07:22:45 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor 3
